Molecular genetics of drug addiction and related co-morbidities (R01)
National Institutes of Health · Opportunity PA-07-073
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse and the National Institute of Mental Health, National Institutes of Health, is to solicit Research Project Grant (R01) applications from institutions/organizations that propose to identify chromosomal loci and/or genetic variation in genes and haplotypes that are associated with either increased or decreased vulnerability to, dependence on, and/or treatment response for addiction to stimulants (e.g., cocaine, amphetamine, caffeine), narcotics (e.g. opiates), nicotine, benzodiazepines, barbiturates, cannabis, hallucinogens, and/or multiple drugs of abuse and/or their associated mental co-morbidities (e.g., major depression, schizophrenia, bipolar disorder) in human beings or animal models. Similarly, there is interest in chromosomal loci and/or genetic variation in genes and haplotypes that are associated with differences in responses to treatment for addiction to drugs of abuse, and treatments for co-morbid disorders -Mechanism of Support. This FOA will utilize the NIH Research Project Grant R01 award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |